Balertatug

巴乐妥塔单抗

Report date: 2025/11/10 15:47:08

Base Information

Drug NameBalertatug
Drug Alias Nameh1F6VorsetuzumabSGN-70
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD70 antigen inhibitors
TargetsCD70 antigen
Therapy Area/IndicationsInflammationAutoimmune DiseasesPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen Inc
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune DiseasesPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A